

PROLACTINOMA - THE MOST COMMON PITUITARY TUMOR. A LITERATURE REVIEW

KRZYSZTOF OLCZYK¹, KACPER ZAJĄC¹, PATRYCJA SZCZĘSNY¹,
AGATA KUPCZAK², IWONA CHORAŻYCZEWSKA²

¹*Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland*

²*Department of Sports Medicine and Exercise Physiology, Medical University of Silesia, Katowice, Poland*

E-mail: krzysztof.olczyk@interia.pl

Abstract

The most common neoplastic change in the pituitary gland is a prolactinoma. Its presence leads to an increase in prolactin levels in the body, known as hyperprolactinemia. This tumour is most frequently diagnosed in young women due to menstrual disorders and the fertility issues it causes, although hyperprolactinemia affects both genders. Diagnosis is not complicated, but certain issues, such as the "hook effect" and macroprolactinemia, can pose challenges to establishing an accurate diagnosis. The primary treatment method involves the use of dopamine agonists, most commonly cabergoline. However, cases of resistance to this method of normalizing prolactin levels, despite using the highest, well-tolerated patient doses, do occur. Other treatment techniques include surgical methods and radiotherapy, but they may also prove ineffective at times. A literature review indicates a continuous increase in researchers' interest in new treatment methods for cases resistant to standard therapeutic approaches or highly invasive pituitary tumours. An example of this is the use of temozolomide in treatment. Research is also underway on other groups of drugs, but there is still insufficient data about them to incorporate them into standard procedures. Therefore, it is crucial to deepen knowledge in this area and conduct further observations.

Key words: sprolactinoma, dopamine agonists, temozolomide, fertility issues, hypogonadism

DOI: 10.19260/PJAS.2023.9.3.03

Introduction

Prolactinoma is the most common pituitary gland tumour originating from lactotroph cells, causing autonomous secretion of prolactin. The incidence of this tumour between the ages of 20 and 50 varies between men and women, while after the sixth decade of life, it becomes similar in both sexes [1]. This difference may be attributed to the fact that in young women, symptoms related to hyperprolactinemia-induced hypogonadism (infertility, amenorrhea) motivate them to seek prompt medical consultation. In contrast, in older age, the frequency is similar in both sexes because the diagnosis is typically based on the mass effect of the tumour [2].

Predisposing Factors

Despite the fact that a significant portion of pituitary tumours occurs sporadically, prolactinoma may also have a genetic basis and be associated with certain hereditary syndromes. These syndromes include multiple endocrine neoplasia type 1 and 4 (MEN-1, MEN-4), familial isolated pituitary adenomas (FIPA), and Carney's syndrome [3,4,5].

A genetic defect in the case of prolactinoma may lead to a more aggressive tumour development and a weaker response

to standard dopamine agonist (DA) treatment [3]. Therefore, it can be concluded that genetic counselling may be valuable for individuals with a family history of the condition.

Prolactinoma and Fertility

Elevated prolactin levels in the blood are one of the most common causes of secondary hypogonadism and infertility in both sexes [6]. Prolactin excess affects reproductive function centrally and peripherally. Centrally, it inhibits the release of gonadotropin-releasing hormone (GnRH), leading to reduced gonadotropin secretion, promoting hypogonadism and infertility [6]. Peripherally, it acts to suppress the synthesis and secretion of sex hormones, specifically oestrogens and progesterone in women. In men, prolactin receptors are present on epithelial cells of ducts, Leydig cells, and Sertoli cells. Through these receptors, prolactin inhibits the activity of these cells, negatively impacting steroidogenesis, spermatogenesis, and the secretory functions of male reproductive organs [6,7].

Symptoms

A pituitary adenoma can have a mass effect, resulting in headaches, pituitary insufficiency, or visual disturbances. Elevated

prolactin (PRL) levels in the blood in both sexes lead to hypogonadism, infertility, galactorrhoea, weight gain, delayed puberty, osteoporosis, and osteopenia. Additionally, in men, there may be erectile dysfunction, decreased libido, or gynecomastia, but these symptoms are sometimes mild and can be underestimated, leading to delayed diagnosis [8]. Menstrual irregularities or galactorrhoea in women typically prompt them to seek prompt medical consultation.

Prolactin also directly influences pancreatic β cells and adipocytes, negatively affecting metabolic profiles. This results in an unfavourable lipid profile, insulin resistance, impaired glucose tolerance, and ultimately abdominal obesity and metabolic syndrome in over 30% of patients [9].

Hyperprolactinemia, by influencing the pituitary and the release of gonadotropins, leads to reduced oestrogen secretion in women. This causes accelerated bone turnover, particularly affecting trabecular bone more than cortical bone. The skeletal system is also weakened in men under the influence of elevated prolactin levels, but it is not yet known whether this is due to a deficiency of testosterone or oestradiol. In both sexes, there is a reduction in bone mineral density (BMD), especially in the lumbar spine, and to a lesser extent in the femoral neck. Moreover, the duration of the disease is strongly correlated with the severity of bone loss, thus untreated prolactinoma is associated with a significant increase in the risk of fractures, especially in the lumbar spine [10,11].

Symptoms in women after the menarche and in women before menopause may vary depending on prolactin levels in the blood:

Moderate increase in prolactin levels (<2.3 mmol/l; up to 50 $\mu\text{g/l}$) – decreased libido, sometimes galactorrhoea, infertility, corpus luteum insufficiency, or menstrual irregularities.

Prolactin levels within the range of 2.3-4.5 nmol/l (50-100 $\mu\text{g/l}$) – often galactorrhoea, infrequent menstruation, or sometimes amenorrhea, or decreased libido.

Markedly elevated prolactin levels (>4.5 nmol/l; >100 $\mu\text{g/l}$) – hypogonadism, amenorrhea, or galactorrhoea [12].




Fig. 1 Clinical Symptoms of Hyperprolactinemia [13].

Diagnosis

Various physiological, pathological states, and certain medications can influence the elevation of prolactin levels in the blood (Figure 2), so it is essential to exclude them before establishing a diagnosis [14]. To identify a pituitary tumour, the concentration of PRL in the serum should be examined. Breast examination should not be performed on patients complaining of galactorrhoea before the PRL test, as nipple stimulation can result in increased PRL levels [14,15]. A concentration slightly above the upper limit of normal can be challenging in diagnosis. In such cases, the test can be repeated after a night of sleep deprivation, taking 2 to 3 samples at intervals of 15-20 minutes to minimize pulsatile PRL secretion [15].

When the prolactin concentration is >9 nmol/l (200 $\mu\text{g/l}$), the likelihood of a prolactinoma is very high, and it is quite substantial at concentrations within the range of 150-200 $\mu\text{g/l}$. An imaging study of the pituitary gland is then recommended, preferably using magnetic resonance imaging (MRI) [12, 14,15]. In the case of a concentration exceeding 500 $\mu\text{g/l}$, a macroprolactinoma (pituitary tumour larger than 10 mm) can likely be diagnosed. Confirmation of the diagnosis must be preceded by an imaging study. Currently, the gold standard is gadolinium-enhanced pituitary magnetic resonance imaging. Computed tomography (CT) is reserved only for individuals with contraindications to MRI, as it is less effective, especially for small tumours [14,16]. Contraindications to MRI include patients with implanted heart defibrillators, clips in brain aneurysms, carotid arteries, aorta, cochlear implants, Swan-Ganz catheters, or pregnant women. MRI in pregnant women is justified only when there is a sudden impairment of the visual field due to tumour growth and is performed in the second trimester of pregnancy [15]. For patients with a tumour larger than 10 mm (macroprolactinoma) compressing the optic chiasm, a visual field examination is recommended.

Physiological	Pharmacological	Pathological
Stress	Neuroleptics	Prolactinoma
Sleep	Selective serotonin reuptake inhibitor	Non-functioning pituitary tumors
Lunch or dinner	Histamine H ₂ receptor blocker	
Chest wall stimulation	Methyldopa	Empty sella syndrome
Pregnancy	Verapamil	Infiltrative disorders or CNS masses
	Reserpine	
	Metoclopramide	Hypothyroidism
	Protease inhibitors	Renal failure, idiopathic

Fig.2 Causes of hyperprolactinemia [17].

The diagnostic criteria include the presence of symptoms such as amenorrhea-galactorrhoea, erectile dysfunction in men, a significant increase and lack of variability in PRL levels

in the serum, as well as the presence of a pituitary adenoma in MRI or CT scans. Other causes of hyperprolactinemia and the occurrence of macroprolactinemia should be ruled out before establishing the diagnosis [13].




Fig. 3 MRI Characteristics of the Prolactinoma Subgroups Characteristic MRI-findings for cystic-, solid micro-, and solid macroprolactinomas in coronal (T2 and T1 postcontrast sequences) and sagittal (T1 postcontrast sequence) planes. The right-most panel demonstrates median tumour sizes in each group, with interquartile range [18].

Macroprolactin

Macroprolactin is an isoform of prolactin with a higher molecular mass and lower biological activity than monomeric Prolactin. The majority of Prolactin in the blood exists in a monomeric form (23 kDa), but occasionally dimers ("big Prolactin" – 50 kDa) and larger polymeric forms ("big-big Prolactin" – 150 kDa) may be present [19]. Macroprolactin, on the other hand, is a complex of IgG with monomeric prolactin. As a result, hyperprolactinemia is the consequence of low renal clearance of prolactin and reduced dopaminergic tone. Although symptoms occur much less frequently in the case of macroprolactin, they resemble those present in monomeric hyperprolactinemia [20]. Determining macroprolactin levels is therefore helpful in patients with asymptomatic hyperprolactinemia as it aids in excluding true hyperprolactinemia, which requires appropriate treatment [14,21].

"Hook Effect"

The diameter of a prolactinoma correlates with the prolactin concentration. In cases where there is a significant discrepancy between a large pituitary tumour and a moderate elevation of prolactin levels, sample dilution in a 1:100 ratio can be applied. This helps identify an artifact present in laboratory results that lowers the prolactin level, known as the "hook effect" [12,14]. It occurs when using certain immunological tests, such as the ELISA test. The "hook effect" is associated with a characteristic binding curve that increases with the analyte concentration in the sample, but at a certain point, exceeding the test components' capacity, the curve drops. This effect can mask the correct diagnosis and erroneously lead to the conclusion of the presence of an inactive pituitary tumour [22].

Menopause – Diagnostic Challenges

During menopause, oestrogen secretion significantly decreases, resulting in less stimulating influence on prolactin secretion and lactotroph cell proliferation. This may pose a challenge in underestimating the frequency of prolactinoma occurrence because in postmenopausal women, fertility is not the primary concern, and the absence of menstruation or galactorrhoea is not prevalent [23]. In postmenopausal patients diagnosed with a prolactinoma, macroprolactinoma or even giant pituitary tumours are most commonly encountered. These tumours, causing a mass effect, can lead to headaches, vision disturbances, and occasionally pituitary apoplexy [24]. Biologically, these tumours are likely similar to those occurring in men, characterized by a relatively rapid growth rate and increased cell proliferation indices [2,24].

Treatment

The goal of treatment is to restore prolactin levels to normal. Effective treatment leads to the alleviation of prolactinoma effects, including visual field disturbances, headaches, cranial nerve paralysis, pituitary insufficiency, hypogonadism, infertility, osteoporosis, and osteopenia [2,14,15]. Since tumours below 10mm rarely grow over the years [25], asymptomatic hyperprolactinemia usually does not require treatment [15]. However, appropriate treatment should be initiated for small symptomatic tumours [25]. Macroprolactinomas, due to their susceptibility to growth and tendency to invade neighbouring structures like the optic chiasm or pituitary stalk, are indications for treatment [19,21].

Dopamine Agonists (DA)

Dopamine agonists (DA) are the first-line treatment. They act similarly to dopamine on dopamine type 2 receptors (D2DR), the activation of which blocks PRL secretion in pituitary cells, inhibits the expression of the PRL gene, and inhibits lactotroph cell proliferation [26]. Cabergoline and bromocriptine are commonly used preparations. Others, such as quinagolide or pergolide, are less commonly used due to their inferior efficacy. Cabergoline is preferred in the first line because of its greater effectiveness [27,28]. In the majority of patients, the normalization of PRL and a reduction in tumour size are achieved through their use [27]. Cabergoline also reduces the intensity of symptoms such as amenorrhoea, infertility, sexual dysfunction, or galactorrhoea. Occasionally, even with DA use, hypogonadism persists, necessitating replacement therapy with caution using oestrogen and progesterone. In men, cabergoline positively impacts symptoms like erectile dysfunction, reduced libido, and abnormal semen parameters. In some cases, testosterone replacement therapy may be necessary for correcting hypogonadism [29]. Care should be taken in testosterone replacement therapy since testosterone can be converted to oestrogen through aromatase, stimulating the proliferation of lactotroph cells, potentially leading to resistance to DA. In the past, to improve fertility and semen quality in persistent hypogonadism, clomiphene citrate was tried, but its effectiveness is still under debate [30].

Impact on Metabolic Disorders

Long-term use of cabergoline in individuals with hyperprolactinemia has a beneficial impact on their metabolic profile. It alleviates or even restores to physiological norms metabolic effects such as insulin resistance, unfavourable lipid profiles, abnormal glucose tolerance, consequently reducing visceral obesity and metabolic syndrome symptoms [31]. Cabergoline leads to weight and waist circumference reduction. Improvement in glucose tolerance and reduced insulin resistance occurs after 6 months of treatment [32]. In cases of resistance to standard cabergoline doses requiring significantly higher doses (around 2-7mg/week), treatment is not futile, even if PRL normalization is not achieved in about 50% of patients. This is because significant improvements are observed in insulin secretion, peripheral sensitivity, fasting glucose levels, and body mass index [33].

Tolerance and Adverse Effects

Among all available drugs reducing PRL levels, cabergoline exhibits the fewest side effects. Common adverse effects include nausea, vomiting, headache, dizziness, and hypotension [34]. Compulsive disorders and psychoses are very rarely observed. Studies have shown that even low doses of bromocriptine can induce mania in postpartum women and psychotic reactions in women with pre-existing mental disorders, but this has not been observed with cabergoline [34].

Resistance to Treatment

Treatment resistance occurs when, despite using maximum tolerated doses, PRL normalization and at least a 50% reduction in tumour size do not occur. The definition is not uniform, as there is ongoing discussion about the specific drug dose at which treatment resistance can be determined [35]. Fortunately, primary resistance is relatively rare. In case of resistance, either increasing the dose to a well-tolerated one or switching to cabergoline from another DA is an option. Studies have shown that despite resistance to quinagolide or bromocriptine, cabergoline caused PRL normalization in over half of the patients.

Pregnancy Considerations

DA use rapidly and effectively restores fertility. Therefore, it is important to advise patients not planning pregnancy to use mechanical contraception along with starting DA treatment [14,15]. For women planning pregnancy, it is recommended to attempt conception after PRL normalization and a clear reduction in tumour mass to minimize the risk of tumour compression on the optic chiasm during pregnancy [14,15]. The risk of tumour enlargement during pregnancy is very low, so once pregnancy is confirmed, DA should be discontinued. Evidence indicates that DA use in the first 6 weeks of foetal development does not increase the risk of adverse effects for the mother nor the foetus, including ectopic pregnancies, spontaneous abortions, trophoblastic diseases, congenital anomalies, or multiple pregnancies [38]. In cases where the mass effect of the tumour and symptoms affecting the visual system occur during pre-

gnancy, resuming treatment is recommended, with bromocriptine being the first choice. There are no contraindications to breastfeeding; however, caution is required in patients with a large residual tumour adjacent to the optic chiasm [39,40].

Surgery and Radiotherapy

In aggressive or malignant prolactinomas, surgical treatment, sometimes combined with radiotherapy, may be required [41]. Surgical treatment involves selectively removing the tumour through the sphenoid sinus. Surgical and medical treatments yield similar results in normalizing PRL; however, for macroprolactinomas, surgical methods are favoured [41]. Radiotherapy is a third-line treatment dedicated to patients for whom pharmacotherapy and surgical treatment have been ineffective. It is not widely used due to the long waiting time for a response and complications such as pituitary insufficiency [42].

Failure of Conventional Treatments

When all treatment lines fail, particularly in aggressive and malignant prolactinomas, an oral alkylating agent, temozolomide, may be used. It has allowed approximately 40% of patients to control tumour growth. Temozolomide is currently recommended as first-line chemotherapy for tumours showing growth [43,44]. If there is a radiological progression of the disease after three treatment cycles, therapy should be discontinued [45]. If temozolomide proves effective, treatment can be continued for a minimum of 6 months or even longer if therapeutic benefit is consistently observed. During treatment, haematological parameters and liver function should be monitored, and attention should be paid to side effects such as fatigue, vomiting, or nausea. An interesting property of temozolomide is its ability to sensitize the tumour to radiation, which may be another option for patients with aggressive and malignant prolactinomas [43,45].

Summary

Diagnosing and treating the majority of prolactinomas cases usually do not present significant challenges. Characteristic clinical symptoms, such as hypogonadism in both sexes, visual disturbances due to the mass effect of the tumour, MRI changes, and elevated prolactin levels in serum, guide the physician to the correct diagnosis. However, certain difficulties may arise, such as the "hook effect" or macroprolactinemia, which can complicate the diagnosis. Treatment typically relies on dopamine agonists, and in more challenging cases, surgical methods or radiotherapy may be necessary. However, these approaches may sometimes prove insufficient, necessitating alternative therapeutic methods, such as the use of temozolomide. Occasionally, these methods fail, highlighting the need for further research into other new drugs or therapeutic approaches that could improve the effectiveness of treatment in highly complicated cases. Currently, there is insufficient data on alternative treatment methods, such as other cytostatic drugs, radionuclides of peptide receptors, mTOR inhibitors, or tyrosine kinase inhibitors to introduce them as standard treatments.

Literature

- [1] Daly AF, Beckers A. The Epidemiology of Pituitary Adenomas. *Endocrinol Metab Clin North Am*. 2020 Sep;49(3):347-355. doi: 10.1016/j.ecl.2020.04.002. Epub 2020 Jun 10. PMID: 32741475.
- [2] Vroonen L, Daly AF, Beckers A. Epidemiology and Management Challenges in Prolactinomas. *Neuroendocrinology*. 2019;109(1):20-27. doi: 10.1159/000497746. Epub 2019 Feb 7. PMID: 30731464.
- [3] Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary disease. *Clin Endocrinol (Oxf)*. 2022 Oct;97(4):424-435. doi: 10.1111/cen.14706. Epub 2022 Mar 29. PMID: 35349723.
- [4] Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. *Endocr Rev*. 2013 Apr;34(2):239-77. doi: 10.1210/er.2012-1013. Epub 2013 Jan 31. PMID: 23371967; PMCID: PMC3610678.
- [5] Alrezk R, Hannah-Shmouni F, Stratakis CA. MEN4 and CDKN1B mutations: the latest of the MEN syndromes. *Endocr Relat Cancer*. 2017 Oct;24(10):T195-T208. doi: 10.1530/ERC-17-0243. Epub 2017 Aug 19. PMID: 28824003; PMCID: PMC5623937.
- [6] Fukuhara N, Nishiyama M, Iwasaki Y. Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma. *Cancers (Basel)*. 2022 Jul 24;14(15):3604. doi: 10.3390/cancers14153604. PMID: 35892862; PMCID: PMC9331865.
- [7] Donato J Jr, Frazão R. Interactions between prolactin and kisspeptin to control reproduction. *Arch Endocrinol Metab*. 2016 Nov-Dec;60(6):587-595. doi: 10.1590/2359-3997000000230. Epub 2016 Nov 24. PMID: 27901187; PMCID: PMC10522168.
- [8] Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. *Presse Med*. 2021 Dec;50(4):104080. doi: 10.1016/j.lpm.2021.104080. Epub 2021 Oct 21. PMID: 34687915.
- [9] Atmaca A, Bilgici B, Ecemis GC, Tuncel OK. Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia. *Endocrine*. 2013 Dec;44(3):756-61. doi: 10.1007/s12020-013-9931-0. Epub 2013 Mar 26. PMID: 23529671.
- [10] Bolanowski M, Halupczok J, Jawiarczyk-Przybyłowska A. Pituitary disorders and osteoporosis. *Int J Endocrinol*. 2015;2015:206853. doi: 10.1155/2015/206853. Epub 2015 Mar 19. PMID: 25873948; PMCID: PMC4383139
- [11] Mills EG, Yang L, Nielsen MF, Kassem M, Dhillon WS, Comninou AN. The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens. *Endocr Rev*. 2021 Nov 16;42(6):691-719. doi: 10.1210/
- endrev/bnab015. Erratum in: *Endocr Rev*. 2021 Oct 01;; PMID: 33901271; PMCID: PMC8599211
- [12] Zgliczyński W, Pańkiewicz-Jankowska E. Prolactinoma. 2023 <https://www.mp.pl/interna/chapter/B16.II.8.4.1> (Access: 28.11.20234.)
- [13] Auremma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the Patient With Prolactinoma. *J Clin Endocrinol Metab*. 2023 Aug 18;108(9):2400-2423. doi: 10.1210/clinem/dgad174. PMID: 36974474; PMCID: PMC10438891.
- [14] Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692. PMID: 21296991.
- [15] Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bornert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. *Clin Endocrinol (Oxf)*. 2006 Aug;65(2):265-73. doi: 10.1111/j.1365-2265.2006.02562.x. PMID: 16886971.
- [16] Petersenn S., Fleseriu M., Casanueva, F.F. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. *Nat Rev Endocrinol* 19, 722–740 (2023). <https://doi.org/10.1038/s41574-023-00886-5>
- [17] Christianson, M., King, J., & Zacur, H. (2015). Hyperprolactinemia. In E. Bieber, J. Sanfilippo, I. Horowitz, & M. Shafi (Eds.), *Clinical Gynecology* (pp. 929-941). Cambridge: Cambridge University Press. doi:10.1017/CBO9781139628938.062.
- [18] Nevzati E, Chatain GP, Carr SB, Lillehei KO, Kerr JM. Surgical management considerations in cystic prolactinomas-a single center case series. *Endocrine*. 2020 Jan;67(1):58-66. doi: 10.1007/s12020-019-02076-8. Epub 2019 Nov 26. PMID: 31773633.
- [19] Biagetti B, Ferrer Costa R, Alfayate Guerra R, Álvarez García E, Berlanga Escalera E, Casals G, et al. Macroprolactin: From laboratory to clinical practice. *Endocrinol Diabetes Nutr (Engl Ed)*. 2022 Jan;69(1):63-69. doi: 10.1016/j.endien.2022.01.001. Epub 2022 Feb 16. PMID: 35232561.
- [20] Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. *Arq Bras Endocrinol Metabol*. 2014 Feb;58(1):9-22. doi: 10.1590/0004-2730000003002. PMID: 24728159.
- [21] Che Soh NAA, Yaacob NM, Omar J, Mohammed Jelani A, Shafii N, Tuan Ismail TS, et al. Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*. 2020 Nov 6;17(21):8199. doi: 10.3390/ijerph17218199. PMID: 33171973; PMCID: PMC7664288.

- [22] Raverot V, Perrin P, Chanson P, Jouanneau E, Brue T, Raverot G. Prolactin immunoassay: does the high-dose hook effect still exist? *Pituitary*. 2022 Aug;25(4):653-657. doi: 10.1007/s11102-022-01246-8. Epub 2022 Jul 6. PMID: 35793045.
- [23] Auriemma RS, Pirchio R, Pivonello R, Colao A. Hyperprolactinemia after menopause: Diagnosis and management. *Maturitas*. 2021 Sep;151:36-40. doi: 10.1016/j.maturitas.2021.06.014. Epub 2021 Jul 3. PMID: 34446277.
- [24] Cocks Eschler D, Javanmard P, Cox K, Geer EB. Prolactinoma through the female life cycle. *Endocrine*. 2018 Jan;59(1):16-29. doi: 10.1007/s12020-017-1438-7. Epub 2017 Nov 24. PMID: 29177641.
- [25] Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 2: Treatment and management strategies. *J Clin Neurosci*. 2015 Oct;22(10):1568-74. doi: 10.1016/j.jocn.2015.03.059. Epub 2015 Aug 1. PMID: 26243714.
- [26] Ogilvie CM, Milsom SR. Dopamine agonists in the treatment of prolactinoma: are they still first choice? *Intern Med J*. 2011 Feb;41(2):156-61. doi: 10.1111/j.1445-5994.2010.02410.x. PMID: 21138511.
- [27] Sabuncu T, Arıkan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. *Intern Med*. 2001 Sep;40(9):857-61. doi: 10.2169/internalmedicine.40.857. PMID: 11579944.
- [28] Arduc A, Gokay F, Isik S, Ozuguz U, Akbaba G, Tutuncu Y, et al. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. *J Endocrinol Invest*. 2015 Apr;38(4):447-53. doi: 10.1007/s40618-014-0212-4. Epub 2014 Nov 25. PMID: 25421155.
- [29] Piskinpaşa H, Turgut S. The factors associated with the persistence of hypogonadism in male patients with prolactinoma. *Neuro Endocrinol Lett*. 2022 Sep 16;43(3):154-160. PMID: 36179726.
- [30] Scovell JM, Khera M. Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male. *Eur Urol Focus*. 2018 Apr;4(3):321-323. doi: 10.1016/j.euf.2018.07.033. Epub 2018 Aug 18. PMID: 30131284.
- [31] Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. The effects of hyperprolactinemia and its control on metabolic diseases. *Expert Rev Endocrinol Metab*. 2018 Mar;13(2):99-106. doi: 10.1080/17446651.2018.1434412. Epub 2018 Feb 7. PMID: 30058862.
- [32] Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. *Neuroendocrinology*. 2015;101(1):66-81. doi: 10.1159/000371851. Epub 2015 Jan 9. PMID: 25592453.
- [33] Pirchio R, Auriemma RS, Solari D, Arnesi M, Pivonello C, Negri M, et al. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment. *Front Endocrinol (Lausanne)*. 2021 Nov 30;12:769744. doi: 10.3389/fendo.2021.769744. PMID: 34917030; PMCID: PMC8670228.
- [34] Castinetti F, Albarel F, Amodru V, Cuny T, Dufour H, Graillon T, et al. The risks of medical treatment of prolactinoma. *Ann Endocrinol (Paris)*. 2021 Feb;82(1):15-19. doi: 10.1016/j.ando.2020.12.008. Epub 2020 Dec 26. PMID: 33373604. 91
- [35] Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. *Neuroendocrinology*. 2019;109(1):42-50. doi: 10.1159/000495775. Epub 2019 Mar 18. PMID: 30481756.
- [36] Vermeulen E, D'Haens J, Stadnik T, Unuane D, Barbe K, Van Velthoven V, Gläser S. Predictors of dopamine agonist resistance in prolactinoma patients. *BMC Endocr Disord*. 2020 May 19;20(1):68. doi: 10.1186/s12902-020-0543-4. PMID: 32429916; PMCID: PMC7236128.
- [37] Levin G, Rottenstreich A. Prolactin, prolactin disorders, and dopamine agonists during pregnancy. *Hormones (Athens)*. 2019 Jun;18(2):137-139. doi: 10.1007/s42000-018-0071-z. Epub 2018 Oct 19. PMID: 30341577.
- [38] O'Sullivan SM, Farrant MT, Ogilvie CM, Gunn AJ, Milsom SR. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. *Aust N Z J Obstet Gynaecol*. 2020 Jun;60(3):405-411. doi: 10.1111/ajo.13070. Epub 2019 Oct 3. PMID: 31583693.
- [39] Pivonello R, De Martino MC, Auriemma RS, Alviggi C, Grasso LF, Cozzolino A, et al. Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. *J Endocrinol Invest*. 2014 Feb;37(2):99-112. doi: 10.1007/s40618-013-0019-8. Epub 2014 Jan 16. Erratum in: *J Endocrinol Invest*. 2014 Jun;37(6):601-2. PMID: 24497208.
- [40] Souteiro P, Belo S, Carvalho D. Dopamine agonists in prolactinomas: when to withdraw? *Pituitary*. 2020 Feb;23(1):38-44. doi: 10.1007/s11102-019-00989-1. PMID: 31556013.
- [41] Donoho DA, Laws ER Jr. The Role of Surgery in the Management of Prolactinomas. *Neurosurg Clin N Am*. 2019 Oct;30(4):509-514. doi: 10.1016/j.nec.2019.05.010. Epub 2019 Jul 2. PMID: 31471058.
- [42] Valea A, Sandru F, Petca A, Dumitrascu MC, Carsoate M, Petca RC, et al. Aggressive prolactinoma (Review). *Exp Ther Med*. 2022 Jan;23(1):74. doi: 10.3892/etm.2021.10997. Epub 2021 Nov 24. PMID: 34934445; PMCID: PMC8652381.

- [43] Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T. Aggressive pituitary tumours and pituitary carcinomas. *Nat Rev Endocrinol*. 2021 Nov;17(11):671-684. doi: 10.1038/s41574-021-00550-w. Epub 2021 Sep 7. PMID: 34493834.
- [44] McCormack A. Temozolomide in aggressive pituitary tumours and pituitary carcinomas. *Best Pract Res Clin Endocrinol Metab*. 2022 Dec;36(6):101713. doi: 10.1016/j.beem.2022.101713. Epub 2022 Oct 13. PMID: 36274026.
- [45] Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. *Eur J Endocrinol*. 2018 Jan;178(1):G1-G24. doi: 10.1530/EJE-17-0796. Epub 2017 Oct 18. PMID: 29046323.

Received: 2023

Accepted: 2023